QQ客服 官方微博 反馈留言

	First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).
	Shi, Yuankai; Wang, Lin; Han, Baohui; Li, Wei; Yu, Ping; Liu, Yunpeng; Ding, Cuimin; Song, Xia; Yong, Ma Zhi; Ren, Xinling
	2016
卷号	34期号:15
ISSN号	0732-183X
DOI	10.1200/JCO.2016.34.15_suppl.9041
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6384893
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Shi, Yuankai,Wang, Lin,Han, Baohui,et al. First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).[J],2016,34(15).
APA	Shi, Yuankai.,Wang, Lin.,Han, Baohui.,Li, Wei.,Yu, Ping.,...&Tan, Fenlai.(2016).First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE)..,34(15).
MLA	Shi, Yuankai,et al."First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).".34.15(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。